|
Bavarian Nordic AS - Company Profile Snapshot
| Company Profile: |
Bavarian Nordic AS |
| Ticker: |
BAVA |
| Exchanges: |
CPH |
| 2008 Sales: |
208,810,000 |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
DENMARK |
| Employees: |
294 |
Business Description
Bavarian Nordic AS. The Group's principal activities are development and production of vaccines and immune therapy products. The Group applies gene therapy and new methodologies in vaccine delivery. The Group utilises three proprietary delivery technologies for its product development programmes: a pox virus vector, a retroviral vector and a cell encapsulation technology. The main product of the Group is the manufacture of smallpox vaccine. The ongoing clinical programmes involve HIV, malignant melanoma, smallpox and cancer research. The Group operates in Denmark, Germany, the US and Singapore.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
